Influenza
Conditions
Keywords
Influenza, Flu, Flu A, Influenza A
Brief summary
The purpose of this study is to evaluate the safety and pharmacokinetics of MEDI8852 compared to placebo when administered to healthy adult subjects.
Detailed description
This is a phase 1, single-dose, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and pharmacokinetics of MEDI8852 compared to placebo when administered to healthy adult subjects. Approximately 40 subjects will be entered to receive treatment across 4 fixed dose cohorts at 1 site. Investigational product will be delivered intravenously (IV). A total of 4 different dose levels of investigational product will be evaluated across the cohorts. Subjects will be followed for approximately 100 days.
Interventions
DRUGMEDI8852
DRUGPlacebo
Sponsors
MedImmune LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 18 through 65 years at the time of screening 2. Weight ≥ 45 kg and ≤ 110 kg at screening 3. Healthy by medical history, physical examination, and baseline safety laboratory studies. 4. Systolic blood pressure (BP) \< 140 mm Hg and diastolic BP \< 90 mm Hg at screening 5. Electrocardiogram without clinically significant abnormalities at screening 6. Able to complete the follow-up period through Day 101 as required by the protocol 7. Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 28 days prior to the first dose of investigational product and must agree to continue using such precautions through Day 101 of the study
Exclusion criteria
1. Acute illness, including fever \> 99.5°F, on day prior to or day of planned dosing 2. Any drug therapy within 7 days prior to Day 1 (except contraceptives or a single use of acetaminophen, aspirin, antihistamine. and other nutritional supplements that have not been taken for at least 30 days prior to enrollment, are not exclusionary. 3. Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 2 months prior to screening 4. Receipt of immunoglobulin or blood products within 6 months prior to screening 5. Receipt of any vaccine within 14 days prior to investigational product dosing or planned receipt of any influenza vaccine within 100 days after investigational product dosing 6. Either history of active infection with hepatitis B or C or positive test for hepatitis C or for hepatitis B surface antigen at screening 7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or serum creatinine above the upper limit of normal or hemoglobin, white blood cell count, or platelet count below the lower limit of normal at screening 8. History of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in previous 5 years 9. Pregnant or nursing mother 10. History of alcohol or drug abuse within the past 2 years tha OR positive Class A drug screen for amphetamines, barbiturates, opiates, or cocaine at screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Adverse Events as a Measure of Safety and tolerability of MEDI8852 | 100 days postdose | Occurrence of adverse events, serious adverse events, adverse events of special interest, and new onset chronic disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of MEDI8852 in serum: time to maximum serum concentration (Cmax) | 100 days postdose | This variable will be estimated for MEDI8852 in the IV cohorts where the data allow. |
| Pharmacokinetics of MEDI8852 in serum: area under the concentration time curve from 0 to t (AUC 0-t) and from 0 to infinity (AUC 0-inf) | 100 days postdose | This variable will be estimated for MEDI8852 in the IV cohorts where the data allow. |
| Pharmacokinetics of MEDI8852 in serum:volume at steady state (Vss) | 100 days postdose | This variable will be estimated for MEDI8852 in the IV cohorts where the data allow. |
| Pharmacokinetics of MEDI8852 in serum: terminal-phase elimination (t½) | 100 days postdose | This variable will be estimated for MEDI8852 in the IV cohorts where the data allow. |
| Pharmacokinetics of MEDI8852 in serum: systemic clearance (CL) | 100 days postdose | This variable will be estimated for MEDI8852 in the IV cohorts where the data allows. |
| Incidence of anti-drug antibody to MEDI8852 in serum | 100 days postdose | This variable will be estimated for MEDI8852 in the IV cohorts where the data allow. |
Countries
United States
Outcome results
None listed